Pharmacologic Trials in the Treatment of Cerebellar Tremor

Koller, William C.

doi:10.1001/archneur.1984.04050150058017

Cited by 60 publications

(24 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other drugs used include carbamazepine, clonazepam, isoniazid and buspirone. [77][78][79] Levetiracetam seemed to work in a class III level of evidence study but not according to a class I level of evidence study. [80,81] The evidence for beneficial effects of cannabinoids on MS-related tremor is weak.…”

Section: Tremormentioning

confidence: 99%

Role of Cannabinoids in Multiple Sclerosis

Zajicek

Apostu

2011

CNS Drugs

View full text Add to dashboard Cite

Although extracts from the cannabis plant have been used medicinally for thousands of years, it is only within the last 2 decades that our understanding of cannabinoid physiology and the provision of evidence for therapeutic benefit of cannabinoids has begun to accumulate. This review provides a background to advances in our understanding of cannabinoid receptors and the endocannabinoid system, and then considers how cannabinoids may help in the management of multiple sclerosis (MS). The relative paucity of treatments for MS-related symptoms has led to experimentation by patients with MS in a number of areas including the use of cannabis extracts. An increasing amount of evidence is now emerging to confirm anecdotal reports of symptomatic improvement, particularly for muscle stiffness and spasms, neuropathic pain and sleep and bladder disturbance, in patients with MS treated with cannabinoids. Trials evaluating a role in treating other symptoms such as tremor and nystagmus have not demonstrated any beneficial effects of cannabinoids. Safety profiles of cannabinoids seem acceptable, although a slow prolonged period of titration improves tolerability. No serious safety concerns have emerged. Methodological issues in trial design and treatment delivery are now being addressed. In addition, recent experimental evidence is beginning to suggest an effect of cannabinoids on more fundamental processes important in MS, with evidence of anti-inflammation, encouragement of remyelination and neuroprotection. Trials are currently under way to test whether cannabinoids may have a longer term role in reducing disability and progression in MS, in addition to symptom amelioration, where indications are being established.

show abstract

Section: Tremormentioning

confidence: 99%

Role of Cannabinoids in Multiple Sclerosis

Zajicek

Apostu

2011

CNS Drugs

View full text Add to dashboard Cite

show abstract

“…A clear benefit of β -blockers could only be demonstrated in essential tremor whereas propranolol was not effective in patients with cerebellar tremor (class III evidence [153]). Besides this, some patients apparently may profit from treatment with β-blockers since these drugs will mitigate psychic agitation and thus reduce tremor.…”

Section: Ataxia and Tremormentioning

confidence: 99%

“…Isoniazid has been used in patients with cerebellar tremor with conflicting results (class III evidence [153, 161]). Adverse effects may limit treatment.…”

Section: Ataxia and Tremormentioning

confidence: 99%

See 1 more Smart Citation

Symptomatic Treatment of Multiple Sclerosis

2006

View full text Add to dashboard Cite

Besides immunomodulation and immunosuppression, the specific treatment of symptoms is an essential component of the overall management of multiple sclerosis (MS). Symptomatic treatment is aimed at the elimination or reduction of symptoms impairing the functional abilities and quality of life of the affected patients. Moreover, with symptomatic treatment the development of a secondary physical impairment due to an existing one may be avoided. Many therapeutic techniques as well as different drugs are used for the treatment of MS symptoms, but only a few of them have been investigated, especially in MS patients, and are approved by the national health authorities. Despite an overwhelming number of publications, only a few evidence-based studies exist and consensus reports are very rare, too. Therefore, it seemed necessary to develop a consensus statement on symptomatic treatment of MS comprising existing evidence-based literature as well as therapeutic experience of neurologists who have dealt with these problems over a long time. This consensus paper contains proposals for the treatment of the most common MS symptoms: disorders of motor function and coordination, of cranial nerve function, of autonomic, cognitive, and psychological functions as well as MS-related pain syndromes and epileptic seizures.

show abstract

“…Current Despite the functional limitations caused by MS tremor, relatively few studies have described the effects of medication on reducing tremor severity. Most drugs studied for their ability to lessen the effect of tremor have shown either negative results (eg, cannabis 6,7 and propranolol 8 ) or possible benefit that was not replicated (eg, levetiracetam 9,10 and ondansetron 11,12 ) or were poorly tolerated (isoniazid [13][14][15][16] ). However, negative studies do not preclude the possibility that available drugs may provide a measure of relief from tremor symptoms for some patients.…”

mentioning

confidence: 99%

Symptomatic Management of Multiple Sclerosis–Associated Tremor Among Participants in the NARCOMS Registry

Meador

Salter

Rinker

2016

International Journal of MS Care

View full text Add to dashboard Cite

Background: Tremor affects 25% to 58% of patients with multiple sclerosis (MS) and is associated with poor prognosis and increased disability. MS-related tremor is difficult to treat, and data regarding patientreported characterization and response to treatment are limited. We describe the symptomatic treatment of tremor in 508 enrollees in the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry who self-reported tremor.

show abstract

Pharmacologic Trials in the Treatment of Cerebellar Tremor

Cited by 60 publications

References 9 publications

Role of Cannabinoids in Multiple Sclerosis

Role of Cannabinoids in Multiple Sclerosis

Symptomatic Treatment of Multiple Sclerosis

Symptomatic Management of Multiple Sclerosis–Associated Tremor Among Participants in the NARCOMS Registry

Contact Info

Product

Resources

About